Innate Pharma S.A. Sponsored ADR

IPHA

Healthcare Biotechnology

Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.

1.44 0.04 +2.86%
Market cap
$160.9M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
0/9
ROIC
0.00%
Net debt / EBITDA
0.2×
Dividend safety
n/a
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
0.60 1.27 2.21 2.60
Net Debt/EBITDA
0.00 0.00 0.00 0.00
Debt/Equity
(0.50) (1.04) 5.25 3.51
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(24.57) (59.85) (35.44) (7.88)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026